Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DL-3-n-butylphthalide for chronic cerebral hypoperfusion
ChiCTR2200059143Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic cerebral hypoperfusion (CCH) comparing DL-3-n-butylphthalide with Placebo (2 arms). Primary endpoint: Change in arteriovenous collateral circulation. Planned start May 2022; status: not yet recruiting.
02
Drugs
butylphthalide
03
Conditions
chronic cerebral hypoperfusion (CCH)
Beyond the preview
Go deeper on ChiCTR2200059143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059143.